Fig. 2From: Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)Progression-free survival in patients treated to disease progression. Gem, gemcitabine; HR, hazard ratio; nab-P, nab-paclitaxelBack to article page